135 related articles for article (PubMed ID: 37804754)
41. Lack of congruence between patients' and health professionals' perspectives of adherence to imatinib therapy in treatment of chronic myeloid leukemia: A qualitative study.
Wu S; Chee D; Ugalde A; Butow P; Seymour J; Schofield P
Palliat Support Care; 2015 Apr; 13(2):255-63. PubMed ID: 24524212
[TBL] [Abstract][Full Text] [Related]
42. MicroRNAs in myeloid malignancies.
Gordon JE; Wong JJ; Rasko JE
Br J Haematol; 2013 Jul; 162(2):162-76. PubMed ID: 23679825
[TBL] [Abstract][Full Text] [Related]
43. Patient perspectives of 'Watch and Wait' for chronic haematological cancers: Findings from a qualitative study.
McCaughan D; Roman E; Sheridan R; Hewison A; Smith AG; Patmore R; Howell DA
Eur J Oncol Nurs; 2023 Aug; 65():102349. PubMed ID: 37331194
[TBL] [Abstract][Full Text] [Related]
44. The influence of drug prices, new availability of inexpensive generic imatinib, new approvals, and post-marketing research on the treatment of chronic myeloid leukaemia in the USA.
Kantarjian H; Paul S; Thakkar J; Jabbour E
Lancet Haematol; 2022 Nov; 9(11):e854-e861. PubMed ID: 36174582
[TBL] [Abstract][Full Text] [Related]
45. Costs of haematological adverse events in chronic myeloid leukaemia patients: a retrospective cost analysis of the treatment of anaemia, neutropenia and thrombocytopenia in patients with chronic myeloid leukaemia.
Bouwmans C; Janssen J; Huijgens P; Uyl-de Groot C
J Med Econ; 2009 Jun; 12(2):164-9. PubMed ID: 19606951
[TBL] [Abstract][Full Text] [Related]
46. Specific point mutations that activate v-abl are not found in Philadelphia-negative chronic myeloid leukaemia, Philadelphia-negative acute lymphoblastic leukaemia or blast transformation of chronic myeloid leukaemia.
Melo JV; Goldman JM
Leukemia; 1992 Aug; 6(8):786-90. PubMed ID: 1353550
[TBL] [Abstract][Full Text] [Related]
47. Monocyte-derived dendritic cells from chronic myeloid leukaemia have abnormal maturation and cytoskeletal function that is associated with defective localisation and signalling by normal ABL1 protein.
Brown S; Hutchinson CV; Aspinall-O'Dea M; Whetton AD; Johnson SM; Rees-Unwin K; Burthem J
Eur J Haematol; 2014 Aug; 93(2):96-102. PubMed ID: 24617663
[TBL] [Abstract][Full Text] [Related]
48. Targeted therapy for haematological malignancies: clinical update from the American Society of Hematology, 2004.
Haas M; Lonial S
Expert Opin Investig Drugs; 2005 Sep; 14(9):1161-9. PubMed ID: 16144500
[TBL] [Abstract][Full Text] [Related]
49. State-of-the-art in the treatment of chronic myeloid leukaemia.
Milojkovic D; Apperley J
Curr Opin Oncol; 2008 Jan; 20(1):112-21. PubMed ID: 18043265
[TBL] [Abstract][Full Text] [Related]
50. Oral idarubicin in the treatment of acute myelogenous leukaemia and the blast phase of chronic myeloid leukaemia.
Malik ST; Tucker J; Rohatiner AZ; Brace W; Lister TA
Hematol Oncol; 1989; 7(6):423-7. PubMed ID: 2807180
[TBL] [Abstract][Full Text] [Related]
51. Patient-guided dose reduction of tyrosine kinase inhibitors in chronic myeloid leukaemia (RODEO study): study protocol for a prospective, multicentre, single-arm trial.
Djodikromo MF; Hermens RP; Bemt BJVD; Smit Y; Govers TM; Bekker CL; Blijlevens NM
BMC Cancer; 2023 Mar; 23(1):231. PubMed ID: 36899295
[TBL] [Abstract][Full Text] [Related]
52. Is AMN-107 a step forward from imatinib in the treatment of chronic myeloid leukaemia?
Doggrell SA
Expert Opin Investig Drugs; 2005 Aug; 14(8):1063-6. PubMed ID: 16050798
[TBL] [Abstract][Full Text] [Related]
53. Nilotinib efficacy, safety, adherence and impact on quality of life in newly diagnosed patients with chronic myeloid leukaemia in chronic phase: a prospective observational study in daily clinical practice.
Huguet F; Cayuela JM; Cambier N; Carpentier N; Tindel M; Violet I; Zunic P; Lascaux A; Etienne G;
Br J Haematol; 2019 Dec; 187(5):615-626. PubMed ID: 31394591
[TBL] [Abstract][Full Text] [Related]
54. De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial.
Clark RE; Polydoros F; Apperley JF; Milojkovic D; Rothwell K; Pocock C; Byrne J; de Lavallade H; Osborne W; Robinson L; O'Brien SG; Read L; Foroni L; Copland M
Lancet Haematol; 2019 Jul; 6(7):e375-e383. PubMed ID: 31201085
[TBL] [Abstract][Full Text] [Related]
55. Ponatinib in childhood Philadelphia chromosome-positive leukaemias: an international registry of childhood chronic myeloid leukaemia study.
Millot F; Suttorp M; Versluys AB; Kalwak K; Nelken B; Ducassou S; Bertrand Y; Baruchel A
Eur J Cancer; 2020 Sep; 136():107-112. PubMed ID: 32668374
[TBL] [Abstract][Full Text] [Related]
56. Philadelphia chromosome and/or bcr-abl mRNA-positive primary thrombocytosis: morphometric evidence for the transition from essential thrombocythaemia to chronic myeloid leukaemia type of myeloproliferation.
Pajor L; Kereskai L; Zsdrál K; Nagy Z; Vass JA; Jáksó P; Radványi G
Histopathology; 2003 Jan; 42(1):53-60. PubMed ID: 12493025
[TBL] [Abstract][Full Text] [Related]
57. The significance of home-based portable pump chemotherapy for family caregivers to newly diagnosed patients with acute myeloid leukemia: A qualitative thematic analysis.
Bennich BB; Konradsen H; Renaberg TP; Boesen J; Wind G
Eur J Oncol Nurs; 2022 Dec; 61():102200. PubMed ID: 36240678
[TBL] [Abstract][Full Text] [Related]
58. A case-control study to investigate the risk of leukaemia associated with exposure to benzene in petroleum marketing and distribution workers in the United Kingdom.
Rushton L; Romaniuk H
Occup Environ Med; 1997 Mar; 54(3):152-66. PubMed ID: 9155776
[TBL] [Abstract][Full Text] [Related]
59. Ischaemic priapism as a presentation of chronic myeloid leukaemia.
Villegas Osorio JF; Corchuelo Maíllo C; Cuevas Palomino A; Medina López RA
Arch Esp Urol; 2014 Oct; 67(8):708-11. PubMed ID: 25306990
[TBL] [Abstract][Full Text] [Related]
60. [Translated article] The needs and medication experience of patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: A systematic review.
Cachafeiro Pin AI; Villaverde Piñeiro L; Martín Clavo S; Silva Castro MM
Farm Hosp; 2023; 47(2):T85-T92. PubMed ID: 36870818
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
